Roivant rewrites the Spac script, again
After revealing plans to buy one of its holdings out of a Spac, Roivant itself moves towards a blank-cheque company listing.
Go or no go? The year ends with Covid-19 vaccine approvals in sight
December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.
Bergenbio dream lives on, despite Genmab's broken Axl
Genmab cans its antibody-drug conjugate against Axl kinase, an approach on which Bergenbio has gone all in.
Sumitomo takes out Urovant, and Myovant beckons
With one portfolio asset rejected by the FDA and another looking dicey, Sumitomo looks pretty reliant on Vibegron.
Obseva shows why red flags are worth heeding
A crucial second pivotal trial in uterine fibroids fails to dispel concerns about the company’s linzagolix.
Myovant socks it to Orilissa
Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.
